SuperworthIncyte EPS INCY
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $7.85
- Latest quarter, Q2 FY26
- $2.81
- +38% on a year earlier
- Fiscal year 2025
- $6.41
- +2274% on the year before
Incyte's earnings per share was $7.85 over the twelve months to Jun 30, 2026, up 78% on a year earlier.
In its latest quarter, Q2 FY26, it was $2.81, up 38% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $6.41 | +2274% |
| FY2024 | $0.27 | −90% |
| FY2023 | $2.65 | +74% |
| FY2022 | $1.52 | −64% |
| FY2021 | $4.27 | n/a |
| FY2020 | −$1.40 | −168% |
| FY2019 | $2.05 | +302% |
| FY2018 | $0.51 | n/a |
| FY2017 | −$1.56 | −389% |
| FY2016 | $0.54 | +5300% |
| FY2015 | $0.01 | n/a |
| FY2014 | −$0.32 | n/a |
| FY2013 | −$0.54 | n/a |
| FY2012 | −$0.36 | n/a |
| FY2011 | −$1.48 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.81 | +38% | $7.85 | |
| Q1 FY26 | $1.47 | +84% | $7.08 | |
| Q4 FY25 | $1.46 | +43% | $6.41 | |
| Q3 FY25 | $2.11 | +291% | $5.97 | |
| Q2 FY25 | $2.04 | n/a | $4.40 | |
| Q1 FY25 | $0.80 | +7% | $0.32 | |
| Q4 FY24 | $1.02 | +15% | $0.27 | |
| Q3 FY24 | $0.54 | −29% | $0.14 | |
| Q2 FY24 | −$2.04 | −327% | $0.36 | |
| Q1 FY24 | $0.75 | +650% | $3.30 | |
| Q4 FY23 | $0.89 | +585% | $2.65 | |
| Q3 FY23 | $0.76 | +52% | $1.89 |
Against its peers
Companies in Biotechnology nearest Incyte's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| INCYIncyte | $7.85 | +78% a year |
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| EXELExelixis | $3.18 | +53% a year |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| ONCBeOne Medicines | $0.43 | |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $4.64 |
Where Incyte ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Incyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.